Advertisement

---

BIOTRENDS RESEARCH GROUP

Use of Erythropoiesis Stimulating Agents Has Declined Over the Past Year in the U.S. Dialysis Setting, While Oral Iron Use in Dialysis Has Increased

[2013-06-20] - At Last Measure, Hemoglobin Levels in Dialysis Patients Have Declined, According to a New Report from BioTrends Research Group


Despite the Numerous Agents in Development for the Treatment of Chronic HCV Infections, a Notable Share of Physicians in Europe Lack Awareness of the HCV Pipeline

[2013-06-11] - One Third of Surveyed Specialists in the EU5 were Unable to Cite Any New Therapy in Development for HCV, According to a New Report from BioTrends Research Group


Phosphate Binder Use Has Declined Over the Past Two Years in the U.S. Dialysis Setting, While Sensipar Use in Hemodialysis has Declined Since Last Year

[2013-06-05] - Sevelamer Continues to Lead in Patient Share and Calcium Acetate Use has Declined Compared to Last Year, According to a New Report from BioTrends Research Group


For Multiple Sclerosis Treatment, Prescriber Base for Genzyme's Aubagio Among U.S. Neurologists Has Increased Significantly at Six Months Post-launch, Compared to One and Three Months Post-launch

[2013-05-30] - However, Aubagio's Prescriber Base Continues to Lag Behind That of Novartis's Gilenya at Same Stage of Product Launch, According to a New Report from BioTrends Research Group


Despite Lucentis's Recent Expanded Label for Diabetic Macular Edema, Avastin Remains the Preferred Intravitreal Therapy for Diabetic Macular Edema in the United States

[2013-05-29] - Lucentis's Prescriber Base and Patient Share Have Grown But Cost-Related Obstacles Remain, According to a New Report from BioTrends Research Group


Rheumatoid Arthritis Patients are Moderately to Highly Satisfied with Their Current Drug Therapy, Rating Conventional DMARDs Highest on Ease of Use and Cost

[2013-05-29] - Although Rheumatologists Indicate There is an Unmet Need for New RA Drug Therapies, Most Patients Do Not Want to Switch from Their Current Medication, According to a New Report from BioTrends Research Group


The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments

[2013-05-23] - Sixty Percent of Surveyed Physicians Agree That They Are Beginning To Warehouse HCV Patients Until New Interferon-Free Regimens Are Available, According to a Recently Published BioTrends Report


Advertisement
Most read: scientific news

More:

---


---
Follow us...

google plus Facebook twitter Newsletter

---


---

Plan du site

Actualités

Actualités

Actualités

Réglementaire

Emploi

Annuaires

Dictionnaire

Divers